Cancer Research Cell Death Mechanisms and Cancer Therapy
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

About the Cover

Cover Figure


The Ras subfamily of small GTP-binding proteins is frequently mutated in human cancers. Several lines of evidence suggest that Rac1 is required downstream of Ras-induced transformation. Kissil and colleagues combined conditional activation of K-ras with conditional deletion of Rac1 in a murine model of lung cancer and demonstrated that Rac1 is required for tumorigenesis in vivo. Shown are representative histological findings from K-rasG12D; Rac1 f lox/+ mice (bottom) or K-rasG12D;Rac1flox/flox mice (top) 12 weeks after induction of the tumorigenic program by infection with Adenovirus-Cre. These findings raise the interesting possibility that targeting Rac1 in Ras-mutated tumors may be therapeutically beneficial. For details, see the article by Kissil and colleagues on page 8089 of this issue.

[Table of Contents]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2008 by the American Association for Cancer Research.